Hikma PharmaceuticalsHKMPY 87 FCF Margin % is 7.69% as of Dec. 2025, which is 43% below its 10-year median of 13.51. GuruFocus rates HKMPY with a GF Score™ of 87/100 and a GF Value™ of $56.75 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 958 Drug Manufacturers companies, Hikma Pharmaceuticals ranks better than 54.49% on this metric.
The historical rank and industry rank for Hikma Pharmaceuticals's FCF Margin % or its related term are showing as below:
HKMPY'
s FCF Margin % Range Over the Past 10 Years
Min: 3.55 Med: 13.51 Max: 16.02
Current: 3.55
During the past 13 years, the highest FCF Margin % of Hikma Pharmaceuticals was 16.02%. The lowest was 3.55%. And the median was 13.51%.
HKMPY's FCF Margin % is ranked better than 54.49% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs HKMPY: 3.55
Hikma Pharmaceuticals FCF Margin % Related Terms
Hikma Pharmaceuticals FCF Margin % Historical Data
* Premium members only.
The historical data trend for Hikma Pharmaceuticals's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikma Pharmaceuticals (HKMPY) has a FCF Margin % of 7.69% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Hikma Pharmaceuticals and its competitors. This is 43% below median its historical median of 13.51. Over the past decade, Hikma Pharmaceuticals' FCF Margin % has ranged from 3.55 to 16.02. According to the industry distribution chart, Hikma Pharmaceuticals ranks #436 out of 958 companies in the Drug Manufacturers industry, placing it in the top 45.5%.
Is Hikma Pharmaceuticals' FCF Margin % too high?
Hikma Pharmaceuticals' current FCF Margin % of 7.69% is 43% below median its 10-year median of 13.51. Over the past 10 years, this metric has ranged from a low of 3.55 to a high of 16.02. The Drug Manufacturers industry median FCF Margin % is 2.45. Hikma Pharmaceuticals' value of 7.69% is 214.5% above this industry median. Based on the distribution chart, Hikma Pharmaceuticals ranks #436 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hikma Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikma Pharmaceuticals ranks #436 out of 958 companies for FCF Margin %. This puts Hikma Pharmaceuticals in the upper half of its industry. The industry median FCF Margin % is 2.45. Hikma Pharmaceuticals' value of 7.69% is 214.5% above this benchmark. Historically, Hikma Pharmaceuticals' own FCF Margin % has ranged from 3.55 to 16.02 over the past decade. While the company's 10-year median is 13.51 vs. the industry median of 2.45, Hikma Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hikma Pharmaceuticals's current FCF Margin % of 7.69% is 214.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Hikma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikma Pharmaceuticals's current FCF Margin % is 7.69%, which is 43% below median its own 10-year median of 13.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPY) is currently considered Modestly Undervalued. The stock's GF Value™ is $56.75, compared to a current price of $41.23 — trading 27.3% below its estimated fair value. The current FCF Margin % is 7.69%, which is 43% below median its 10-year median of 13.51 and 214.5% above the Drug Manufacturers industry median of 2.45. Hikma Pharmaceuticals' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPY), the current FCF Margin % is 7.69% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (HKMPY) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of $41.23 is trading 27.3% below its estimated GF Value™ of $56.75.
GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKMPY:
FCF Margin %: 7.69% (43% below median its 10-year median of 13.51)
GF Value™: $56.75 vs. price of $41.23 (27.3% below fair value)
Industry Position: 214.5% above the Drug Manufacturers median (#436 of 958)
No single metric tells the full story. See the HKMPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
87GF Score
Get the complete analysis for HKMPY
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKMPY has been successfully added to your 
